Vivus Files Application For Weight Loss Drug (VVUS)

VIVUS, Inc. VVUS is slightly higher this morning, gaining 0.4% after the company filed a European Marketing Authorization application for QNEXA in the treatment of obesity. Vivus will market its Vivus drug if it is approved by the European Medicines Agency (EMA), which is similar to our FDA. Qnexa is being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. If approved, Qnexa could be recommended for obese or overweight patients by the end of 2011. Vivus said Qnexa had achieved the 10% weight-loss efficacy benchmark over two years, which the EMA set as a benchmark.